CN1304370C - 苊并杂环类化合物及其诱导细胞凋亡和抗肿瘤的应用 - Google Patents
苊并杂环类化合物及其诱导细胞凋亡和抗肿瘤的应用 Download PDFInfo
- Publication number
- CN1304370C CN1304370C CNB2004100504495A CN200410050449A CN1304370C CN 1304370 C CN1304370 C CN 1304370C CN B2004100504495 A CNB2004100504495 A CN B2004100504495A CN 200410050449 A CN200410050449 A CN 200410050449A CN 1304370 C CN1304370 C CN 1304370C
- Authority
- CN
- China
- Prior art keywords
- cell
- acenaphthene
- nitrile
- apoptosis
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000001939 inductive effect Effects 0.000 title claims abstract description 13
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 9
- CWRYPZZKDGJXCA-UHFFFAOYSA-N acenaphthalene Natural products C1=CC(CC2)=C3C2=CC=CC3=C1 CWRYPZZKDGJXCA-UHFFFAOYSA-N 0.000 title description 15
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 title description 8
- -1 Acenaphthene heterocyclic compound Chemical class 0.000 title description 3
- 238000005562 fading Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 33
- 230000006907 apoptotic process Effects 0.000 claims abstract description 29
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 12
- 230000022131 cell cycle Effects 0.000 claims abstract description 9
- 229910052736 halogen Chemical group 0.000 claims abstract description 5
- 125000005843 halogen group Chemical group 0.000 claims abstract 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 230000030833 cell death Effects 0.000 claims description 9
- 239000000411 inducer Substances 0.000 claims description 7
- 230000018199 S phase Effects 0.000 claims description 6
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 6
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 3
- 231100000673 dose–response relationship Toxicity 0.000 claims description 3
- 238000004043 dyeing Methods 0.000 claims description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 21
- 241001465754 Metazoa Species 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 238000001727 in vivo Methods 0.000 abstract description 7
- 230000004614 tumor growth Effects 0.000 abstract description 4
- 230000001093 anti-cancer Effects 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 125000003277 amino group Chemical group 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 28
- 239000006285 cell suspension Substances 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- LWLSVNFEVKJDBZ-UHFFFAOYSA-N N-[4-(trifluoromethoxy)phenyl]-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methyl]piperidine-1-carboxamide Chemical compound FC(OC1=CC=C(C=C1)NC(=O)N1CCC(CC1)CC1=CC(=CC=C1)OC1=NC=C(C=C1)C(F)(F)F)(F)F LWLSVNFEVKJDBZ-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 230000001640 apoptogenic effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000118 anti-neoplastic effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 230000012447 hatching Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 150000003335 secondary amines Chemical class 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000025084 cell cycle arrest Effects 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 101710183280 Topoisomerase Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012434 nucleophilic reagent Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 150000003233 pyrroles Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000005815 base catalysis Methods 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- MAFQLJCYFMKEJJ-UHFFFAOYSA-N ethyl 4-aminobutanoate Chemical compound CCOC(=O)CCCN MAFQLJCYFMKEJJ-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
浓度(μM) | 0.01 | 0.05 | 0.1 | 0.2 | 0.4 | 0.5 | 1 | 2 |
抑制率(%)(3次) | 2 | 6.7 | 31.5 | 53.5 | 68 | 78 | 83.8 | 89.8 |
1.2 | 6 | 31 | 52.2 | 67.5 | 76.6 | 83.4 | 87.8 | |
1.4 | 7.1 | 31.4 | 51.2 | 67.6 | 76.4 | 83.6 | 88.2 | |
平均抑制率(%) | 1.53 | 6.6 | 31.3 | 52.3 | 67.7 | 77.0 | 83.6 | 88.6 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100504495A CN1304370C (zh) | 2004-09-15 | 2004-09-15 | 苊并杂环类化合物及其诱导细胞凋亡和抗肿瘤的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100504495A CN1304370C (zh) | 2004-09-15 | 2004-09-15 | 苊并杂环类化合物及其诱导细胞凋亡和抗肿瘤的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1616428A CN1616428A (zh) | 2005-05-18 |
CN1304370C true CN1304370C (zh) | 2007-03-14 |
Family
ID=34763936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100504495A Expired - Fee Related CN1304370C (zh) | 2004-09-15 | 2004-09-15 | 苊并杂环类化合物及其诱导细胞凋亡和抗肿瘤的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1304370C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010054575A1 (zh) | 2008-11-11 | 2010-05-20 | 大连理工大学 | 苊并杂环类化合物、其环糊精包合物和环糊精配结物以及它们在制备BH3类似物Bcl-2家族蛋白抑制剂中的应用 |
US8614333B2 (en) | 2010-07-28 | 2013-12-24 | Dalian University Of Technology | Acenaphtho heterocyclic compound and application thereof |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1940563B (zh) * | 2005-09-28 | 2010-04-28 | 华东理工大学 | 一种荧光标记试剂 |
CN101723907B (zh) * | 2009-07-25 | 2011-09-14 | 大连理工大学 | 一类邻二氰基苊并吡嗪化合物及其抗肿瘤应用 |
WO2012012941A1 (zh) * | 2010-07-28 | 2012-02-02 | 大连理工大学 | Bcl-2家族蛋白抑制剂,其环糊精包合物、配结物及其在制备bcl-2家族蛋白抑制剂中的应用 |
CN102336700B (zh) * | 2010-07-28 | 2013-11-06 | 大连理工大学 | 一类氨基取代苊并杂环类化合物及其应用 |
WO2012100368A1 (zh) * | 2011-01-25 | 2012-08-02 | 大连理工大学 | 筛选肿瘤细胞的方法及其用途 |
CN111551416B (zh) * | 2020-03-22 | 2021-08-06 | 华南理工大学 | 一种基于细胞膜磷脂酰丝氨酸荧光染色的细菌类凋亡评价方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6048975A (en) * | 1991-09-12 | 2000-04-11 | Hoechst Aktiengesellschaft | Process for the chemical synthesis of oligonucleotides |
CN1410507A (zh) * | 2002-11-14 | 2003-04-16 | 大连理工大学 | 8-氧-8H苊并(1,2-b)吡咯-9-腈荧光发色团及其衍生物 |
-
2004
- 2004-09-15 CN CNB2004100504495A patent/CN1304370C/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6048975A (en) * | 1991-09-12 | 2000-04-11 | Hoechst Aktiengesellschaft | Process for the chemical synthesis of oligonucleotides |
CN1410507A (zh) * | 2002-11-14 | 2003-04-16 | 大连理工大学 | 8-氧-8H苊并(1,2-b)吡咯-9-腈荧光发色团及其衍生物 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010054575A1 (zh) | 2008-11-11 | 2010-05-20 | 大连理工大学 | 苊并杂环类化合物、其环糊精包合物和环糊精配结物以及它们在制备BH3类似物Bcl-2家族蛋白抑制剂中的应用 |
US8614333B2 (en) | 2010-07-28 | 2013-12-24 | Dalian University Of Technology | Acenaphtho heterocyclic compound and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1616428A (zh) | 2005-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107176954B (zh) | 一种egfr抑制剂的药用盐及其晶型、制备方法和应用 | |
CN107266453A (zh) | 作为蛋白激酶抑制剂的新型吡咯并嘧啶化合物 | |
CN1990484A (zh) | 水飞蓟宾酯类衍生物及其制备方法和用途 | |
CN1304370C (zh) | 苊并杂环类化合物及其诱导细胞凋亡和抗肿瘤的应用 | |
CN105705493B (zh) | 喹唑啉衍生物、其制备方法、药物组合物和应用 | |
CN105001168A (zh) | 三烷氧基取代的苯并喹唑啉类酪氨酸激酶抑制剂及其用途 | |
CN102675323B (zh) | 吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途 | |
CN111892580B (zh) | 一种2-氨基-4-(异吲哚啉-2-基)嘧啶-5-甲酰胺衍生物、制备方法及应用 | |
CN108101926B (zh) | 含喹啉酮的嘧啶并五元杂环类化合物、制备方法及其应用 | |
CN111362925B (zh) | 一种4-嘧啶甲酰胺类化合物、药物组合物、制备方法及应用 | |
CN103739616A (zh) | 含噻唑基雷帕霉素类衍生物及其应用 | |
CN106008468A (zh) | 玻玛西尼a晶型、b晶型、c晶型及其制备方法 | |
CN105732409B (zh) | 氨基酸修饰的杂多酸盐化合物及其制备方法和应用 | |
CN1931840A (zh) | 一类dna靶分子及其诱导细胞凋亡和抗肿瘤的应用 | |
CN112110864B (zh) | 一种4-酰胺取代嘧啶类靶向ddr1抑制剂及其制备和抗肿瘤活性的应用 | |
CN110092789B (zh) | 一种吲哚并[2,3-b]咔唑衍生物及其应用 | |
CN1283640C (zh) | 萘类衍生物及其在乏氧体系中的应用 | |
CN103880700B (zh) | O-肉桂酰-氟苯水杨酰胺类化合物及其在制备抗宫颈癌药物中的应用 | |
CN114957340B (zh) | 一种诱导铁死亡的双核铱配合物的制备方法及其应用 | |
CN111777562B (zh) | 一种6-苯氧基取代嘧啶类靶向ddr1抑制剂及其制备和抗肿瘤活性的应用 | |
CN110225913B (zh) | Fgfr4抑制剂晶型及其制备方法 | |
CN105646461A (zh) | S构型4-(取代苯胺基)喹唑啉衍生物及其制备方法和用途 | |
CN117642400A (zh) | 一种fgfr4抑制剂酸式盐及其制备方法和应用 | |
CN117263968A (zh) | 一种基于厄洛替尼修饰的含硼化合物及其应用 | |
CN101817808A (zh) | 黄酮衍生物、其制法及作为α1受体拮抗剂的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Beijing Medconxin Pharmaceutical Technology Co., Ltd. Assignor: Dalian University of Technology Contract record no.: 2011210000059 Denomination of invention: Acenaphthene heterocyclic compound and its cell fading inducing and anti-tumor use Granted publication date: 20070314 License type: Exclusive License Open date: 20050518 Record date: 20110620 |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070314 Termination date: 20130915 |